Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications.
The complexity of cardiovascular responses produced by 5-hydroxytryptamine (5-HT, serotonin), including bradycardia or tachycardia, hypotension or hypertension, and vasodilatation or vasoconstriction, has been explained by the capability of this monoamine to interact with different receptors in the central nervous system (CNS), on the autonomic ganglia and postganglionic nerve endings, on vascular smooth muscle and endothelium, and on the cardiac tissue. Depending, among other factors, on the species, the vascular bed under study, and the experimental conditions, these responses are mainly mediated by 5-HT(1), 5-HT(2), 5-HT(3), 5-HT(4), 5-ht(5A/5B), and 5-HT(7) receptors as well as by a tyramine-like action or unidentified mechanisms. It is noteworthy that 5-HT(6) receptors do not seem to be involved in the cardiovascular responses to 5-HT. Regarding heart rate, intravenous (i.v.) administration of 5-HT usually lowers this variable by eliciting a von Bezold-Jarisch-like reflex via 5-HT(3) receptors located on sensory vagal nerve endings in the heart. Other bradycardic mechanisms include cardiac sympatho-inhibition by prejunctional 5-HT(1B/1D) receptors and, in the case of the rat, an additional 5-ht(5A/5B) receptor component. Moreover, i.v. 5-HT can increase heart rate in different species (after vagotomy) by a variety of mechanisms/receptors including activation of: (1) myocardial 5-HT(2A) (rat), 5-HT(3) (dog), 5-HT(4) (pig, human), and 5-HT(7) (cat) receptors; (2) adrenomedullary 5-HT(2) (dog) and prejunctional sympatho-excitatory 5-HT(3) (rabbit) receptors associated with a release of catecholamines; (3) a tyramine-like action mechanism (guinea pig); and (4) unidentified mechanisms (certain lamellibranch and gastropod species). Furthermore, central administration of 5-HT can cause, in general, bradycardia and/or tachycardia mediated by activation of, respectively, 5-HT(1A) and 5-HT(2) receptors. On the other hand, the blood pressure response to i.v. administration of 5-HT is usually triphasic and consists of an initial short-lasting vasodepressor response due to a reflex bradycardia (mediated by 5-HT(3) receptors located on vagal afferents, via the von Bezold-Jarisch-like reflex), a middle vasopressor phase, and a late, longer-lasting, vasodepressor response. The vasopressor response is a consequence of vasoconstriction mainly mediated by 5-HT(2A) receptors; however, vasoconstriction in the canine saphenous vein and external carotid bed as well as in the porcine cephalic arteries and arteriovenous anastomoses is due to activation of 5-HT(1B) receptors. The late vasodepressor response may involve three different mechanisms: (1) direct vasorelaxation by activation of 5-HT(7) receptors located on vascular smooth muscle; (2) inhibition of the vasopressor sympathetic outflow by sympatho-inhibitory 5-HT(1A/1B/1D) receptors; and (3) release of endothelium-derived relaxing factor (nitric oxide) by 5-HT(2B) and/or 5-HT(1B/1D) receptors. Furthermore, central administration of 5-HT can cause both hypotension (mainly mediated by 5-HT(1A) receptors) and hypertension (mainly mediated by 5-HT(2) receptors). The increasing availability of new compounds with high affinity and selectivity for the different 5-HT receptor subtypes makes it possible to develop drugs with potential therapeutic usefulness in the treatment of some cardiovascular illnesses including hypertension, migraine, some peripheral vascular diseases, and heart failure.
Villalón
Carlos M
CM
Departamento de Farmacobiología, Cinvestav-Coapa, Tenorios 235, Col. Granjas-Coapa, Delegación Tlalpan, 14330 México D.F., Mexico. carlos_villalon@infosel.net.mx
Centurión
David
D
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000503:physiopathology; D002545:Brain Ischemia / Q000188:drug therapy / Q000503:physiopathology; D002320:Cardiovascular Physiological Phenomena / Q000187:drug effects*; D002319:Cardiovascular System / Q000187:drug effects / Q000294:innervation; D005728:Ganglia, Sympathetic / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D008024:Ligands; D008881:Migraine Disorders / Q000188:drug therapy / Q000503:physiopathology; D016491:Peripheral Vascular Diseases / Q000188:drug therapy / Q000503:physiopathology; D011985:Receptors, Serotonin / Q000145:classification / Q000502:physiology*; D012701:Serotonin / Q000494:pharmacology* / Q000502:physiology; D018490:Serotonin Agents / Q000494:pharmacology
D008024:Ligands; D011985:Receptors, Serotonin; D018490:Serotonin Agents; D012701:Serotonin
Lancet. 2001 Oct 13;358(9289):1230-4
11675061
Br J Pharmacol. 1999 Oct;128(3):730-4
10516655
Eur J Pharmacol. 1982 Nov 19;85(2):225-7
6129985
Br J Pharmacol. 1998 Apr;123(8):1561-70
9605562
J Pharmacol Exp Ther. 1981 Jul;218(1):217-30
6113280
Nature. 1952 May 10;169(4306):800-1
14941051
Naunyn Schmiedebergs Arch Pharmacol. 1999 Apr;359(4):331-8
10344532
Pain. 1996 Feb;64(2):315-22
8740609
Eur J Pharmacol. 1989 Sep 22;168(3):369-74
2583242
Behav Brain Res. 1996;73(1-2):157-61
8788495
Br J Clin Pharmacol. 1999 Jan;47(1):75-82
10073743
Arch Int Pharmacodyn Ther. 1995 Jan-Feb;329(1):111-9
7639613
Naunyn Schmiedebergs Arch Pharmacol. 1986 Feb;332(2):124-30
2939353
N Engl J Med. 2004 Mar 11;350(11):1104-10
15014183
J Auton Pharmacol. 1989 Jun;9(3):201-10
2545718
Pain. 1991 Jun;45(3):283-91
1876437
Life Sci. 1999;64(20):1839-47
10350358
Trends Pharmacol Sci. 1999 Dec;20(12):490-5
10603491
Mol Interv. 2005 Oct;5(5):304-11
16249526
Br J Pharmacol. 1991 Apr;102(4):938-42
1855122
Cardiovasc Drugs Ther. 1990 Jan;4 Suppl 1:33-5
2285648
J Exp Biol. 1997;200(Pt 15):2123-35
9320037
Physiol Rev. 1958 Apr;38(2):277-335
13542212
Stroke. 1990 Dec;21(12 Suppl):IV161-3
2148035
Naunyn Schmiedebergs Arch Pharmacol. 1990 Oct;342(4):371-7
2255330
Pain. 1996 Oct;67(2-3):375-8
8951932
Br J Pharmacol. 1995 Dec;116(8):3330-6
8719815
Neuropharmacology. 1997 Jan;36(1):83-91
9144644
Pharmacol Biochem Behav. 2002 Apr;71(4):533-54
11888546
Br J Pharmacol. 1990 Aug;100(4):665-7
2207493
Neuroreport. 1997 Jul 7;8(9-10):2237-40
9243618
Circ Res. 1985 Jul;57(1):46-54
4006105
Pharmacol Rev. 1994 Jun;46(2):157-203
7938165
Life Sci. 1988;43(18):1441-9
3185102
J Neurophysiol. 2004 Oct;92(4):2487-96
15140904
Br J Pharmacol. 1987 Oct;92 (2):417-27
3676602
Br J Pharmacol. 2003 Oct;140(4):725-35
14504136
Naunyn Schmiedebergs Arch Pharmacol. 2004 Sep;370(3):157-66
15365689
J Cardiovasc Pharmacol. 1989 Jan;13(1):45-51
2468935
Eur J Pharmacol. 1993 Jan 5;230(1):103-5
8428599
J Cardiovasc Pharmacol. 1991;17 Suppl 5:S48-53
1717773
Hepatology. 1991 Dec;14(6):1174-8
1959867
Naunyn Schmiedebergs Arch Pharmacol. 2000 Aug;362(2):169-76
10961380
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12
8380639
Br J Pharmacol. 2000 Oct;131(3):562-8
11015308
Neuroscience. 1993 Jul;55(1):235-52
8350989
Biochem Pharmacol. 1994 Aug 17;48(4):683-8
7915903
Arch Int Pharmacodyn Ther. 1985 Oct;277(2):235-52
2933009
Br J Pharmacol. 1995 Sep;116(2):1715-7
8528548
J Neurol. 1991;238 Suppl 1:S53-6
2045832
Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):220-7
14673512
J Biol Chem. 1948 Dec;176(3):1243-51
18100415
Am J Physiol. 1999 Mar;276(3 Pt 2):H944-52
10070078
Pharmacol Ther. 2006 Sep;111(3):674-706
16960982
J Cardiovasc Pharmacol. 1990;15 Suppl 7:S17-34
1702484
Naunyn Schmiedebergs Arch Pharmacol. 2000 Jun;361(6):665-71
10882042
Br J Pharmacol. 1976 Oct;58(2):211-21
184872
J Pharmacol Exp Ther. 1988 Jan;244(1):1-10
2961880
Am J Physiol Regul Integr Comp Physiol. 2003 Mar;284(3):R782-91
12611395
J Neurophysiol. 2004 Oct;92(4):2468-86
15140903
Fed Proc. 1983 Feb;42(2):223-7
6295823
Clin Exp Hypertens. 1994 Nov;16(6):779-98
7858559
J Pharmacol Exp Ther. 1990 Feb;252(2):683-8
1968974
J Physiol. 2005 Feb 15;563(Pt 1):319-31
15611034
Br J Pharmacol. 2000 Jan;129(1):177-83
10694218
Cardiovasc Drugs Ther. 1990 Jan;4 Suppl 1:19-25
2285646
Eur J Pharmacol. 1989 Oct 24;170(1-2):109-11
2612560
J Biol Chem. 1949 Oct;180(3):961-9
18139191
Pharmacol Ther. 1995 May;66(2):339-68
7667401
Neuropharmacology. 1999 Aug;38(8):1083-152
10462127
Br J Pharmacol. 1990 Aug;100(4):879-85
2169944
Circ Res. 2005 Aug 5;97(3):268-76
16002744
Mol Pharmacol. 2000 Jan;57(1):75-81
10617681
Proc West Pharmacol Soc. 2002;45:199-210
12434581
Behav Brain Res. 1996;73(1-2):301-4
8788524
Brain Res Bull. 2001 Nov 15;56(5):425-39
11750788
Br J Pharmacol. 1997 Apr;120(7):1319-27
9105708
Br J Pharmacol. 1993 Nov;110(3):1172-4
8298805
Br J Pharmacol Chemother. 1957 Sep;12(3):323-8
13460238
Am J Physiol Regul Integr Comp Physiol. 2000 Nov;279(5):R1776-86
11049861
Br J Pharmacol. 1991 Jan;102(1):107-12
2043916
Naunyn Schmiedebergs Arch Pharmacol. 1989 Mar;339(3):259-62
2725703
Naunyn Schmiedebergs Arch Pharmacol. 1994 Sep;350(3):225-9
7824037
J Pharmacol Exp Ther. 1990 Jan;252(1):387-95
2137176
Br J Pharmacol. 1995 Sep;116(2):1751-6
8528555
Am J Med. 1995 Sep;99(3):249-54
7653484
Br J Pharmacol. 1992 Oct;107(2):591-6
1422600
Eur J Pharmacol. 1997 Jul 23;331(2-3):169-74
9274976
Naunyn Schmiedebergs Arch Pharmacol. 1996 Nov;354(5):550-6
8938651
Rev Med Interne. 2004 Oct;25(10):720-31
15471598
Neuropharmacology. 1986 Jun;25(6):563-76
2875415
Br J Pharmacol. 1994 Feb;111(2):616-24
8004405
Naunyn Schmiedebergs Arch Pharmacol. 1992 Nov;346(5):482-5
1335123
Stroke. 1990 Dec;21(12 Suppl):IV164-6
2148036
Br J Pharmacol. 1998 Jul;124(5):1001-11
9692787
Cardiovasc Drugs Ther. 1990 Jan;4 Suppl 1:53-8
2285651
Trends Pharmacol Sci. 1998 Aug;19(8):311-6
9745358
Br J Pharmacol. 2001 Mar;132(5):991-8
11226129
Eur J Pharmacol. 1992 Nov 10;222(2-3):185-91
1451731
J Vet Pharmacol Ther. 1994 Jun;17(3):218-25
7933060
Eur J Pharmacol. 2004 Jan 26;484(2-3):287-90
14744615
J Auton Nerv Syst. 1988 Apr;22(3):229-36
3418016
Br J Pharmacol. 1997 Jul;121(6):1187-95
9249256
Naunyn Schmiedebergs Arch Pharmacol. 1988 Jan;337(1):1-8
3368008
Science. 1983 Jul 15;221(4607):273-4
6574604
Naunyn Schmiedebergs Arch Pharmacol. 1987 Oct;336(4):365-73
3431594
Naunyn Schmiedebergs Arch Pharmacol. 2001 Jan;363(1):73-80
11191839
Pharmacol Ther. 2006 Sep;111(3):707-14
16516972
Trends Pharmacol Sci. 1991 Dec;12(12):444-6
1665260
Br J Pharmacol. 2006 Sep;149(1):82-91
16880765
Jpn J Pharmacol. 2002 Jul;89(3):242-8
12184729
Br J Pharmacol. 2007 Jan;150(2):143-52
17160012
Nat Med. 2002 Oct;8(10 ):1129-35
12244304
Eur J Pharmacol. 1994 Feb 3;252(2):161-6
8157057
Pharmacol Ther. 1994;62(3):283-324
7972337
Br J Pharmacol. 2002 Mar;135(6):1531-9
11906967
Circulation. 1999 Jan 5-12;99(1):156-61
9884392
Br J Pharmacol. 1995 Jan;114(2):400-4
7881740
Am J Physiol. 1953 Sep;174(3):436-44
13092269
Eur J Pharmacol. 1988 Jan 5;145(1):67-73
2894997
J Pharmacol Exp Ther. 1985 Oct;235(1):76-80
4045729
Naunyn Schmiedebergs Arch Pharmacol. 1993 May;347(5):471-7
8391650
Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):46-53
15224175
Eur J Pharmacol. 1989 May 19;164(2):213-22
2759173
Cephalalgia. 2002 Dec;22(10):799-806
12485205
Eur J Pharmacol. 1993 Nov 30;250(1):67-75
7907025
Eur J Pharmacol. 2004 Oct 19;502(3):239-42
15476750
Brain Res. 2007 May 4;1144:82-90
17320834
Pharmacol Rev. 1994 Sep;46(3):231-43
7831380
Mol Pharmacol. 1996 Dec;50(6):1567-80
8967979
Life Sci. 1994;54(10):641-4
8107508
Neuropharmacology. 1984 Dec;23(12B):1473-86
6527747
Naunyn Schmiedebergs Arch Pharmacol. 1987 Sep;336(3):245-50
3683595
Life Sci. 1995;57(8):803-12
7637553
Eur J Pharmacol. 1993 Aug 10;240(1):9-20
8405128
J Physiol. 1900 Dec 31;26(1-2):48-71
16992567
Cardiovasc Res. 2005 Mar 1;65(4):869-78
15721867
J Biol Chem. 1948 Jun;174(2):735-41
18865641
Br J Pharmacol. 1993 Feb;108(2):431-5
8448594
Cephalalgia. 1996 Nov;16(7):497-502
8933995
Br J Pharmacol. 2001 Mar;132(5):983-90
11226128
Br J Pharmacol. 2000 Jun;130(3):692-8
10821800
Headache. 1972 Jul;12(2):44-54
5056178
Naunyn Schmiedebergs Arch Pharmacol. 1997 Jul;356(1):90-9
9228195
Br J Pharmacol. 1992 Dec;107(4):1020-8
1467825
Neuropharmacology. 1997 Apr-May;36(4-5):419-28
9225265
Cephalalgia. 2001 Sep;21(7):727-32
11595000
Clin Exp Pharmacol Physiol. 1983 Sep-Oct;10(5):535-42
6315283
Br J Pharmacol. 1988 Aug;94(4):1123-32
2850055
Hypertension. 1991 May;17(5):593-602
2022404
Br J Pharmacol. 1999 Feb;126(3):585-94
10188968
Clin Neuropharmacol. 1996 Apr;19(2):101-28
8777766
Br J Pharmacol. 1995 Nov;116(5):2385-90
8581273
Mol Pharmacol. 1979 Nov;16(3):687-99
530254
Neuropharmacology. 1995 Mar;34(3):255-61
7630480
Chest. 1998 Sep;114(3 Suppl):242S-247S
9741576
Eur J Pharmacol. 1998 Nov 27;362(1):69-72
9865532